A New Strategy to Help Transplanted Insulin-Producing Cells Survive

Islet transplantation—where insulin-producing cells are transplanted to manage Type 1 diabetes—offers real promise. But many transplants fail in the first days and weeks after the procedure. A major reason is hypoxia: the cells don't get enough oxygen during and after transplantation, which damages them and impairs their ability to produce insulin.

Researchers have typically tried to solve this problem by increasing oxygen supply to the cells. A new study suggests a different approach: what if we reduced the cells' need for oxygen instead?

Adenosine is a purine nucleoside—a small molecule your body makes naturally. It plays roles in immune function and controlling metabolism. Scientists at Frontiers in Bioengineering and Biotechnology investigated whether adenosine could help human islet cells tolerate low-oxygen conditions.

When human islets were exposed to very low oxygen (1% oxygen) in the lab, those pretreated with adenosine survived better and maintained their ability to sense blood sugar and release insulin. The adenosine appeared to work by lowering the cells' metabolic demand—essentially putting them in a more energy-efficient state that requires less oxygen.

Importantly, the insulin content that dropped during adenosine treatment bounced back within 96 hours of stopping the treatment, and the protective effects lasted through 48 hours after oxygen was restored.

These findings are laboratory results from human cells studied in controlled conditions. However, they suggest adenosine preconditioning could be a practical tool for improving islet transplant outcomes. The approach is reversible, meaning it doesn't cause permanent changes, and it appears to work without harming the cells.

Adenosine could potentially be used at several stages of the transplant preparation process—during islet culture, when cells are being packaged, or even in newer technologies like 3D bioprinting.

This is early-stage research based on cells grown in a dish. Before adenosine could be used in human transplants, scientists would need to conduct further studies in animal models and eventually clinical trials to confirm safety and effectiveness. The goal remains improving the success rate of islet transplantation, which could eventually offer people with Type 1 diabetes a cell-based therapy option.

Source: Frontiers in bioengineering and biotechnology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.